This proteomic assay was used to identify proteins related to HSP90 inhibition responsiveness according to the most relevant molecular alteration in lung adenocarcinoma such as EGFR and KRAS mutations and ALK translocation. This evidence concerns the gene HSP90AA1 and lung adenocarcinoma.